Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

694
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
694
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

933
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.2K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.2K
Drug Therapy01:28

Drug Therapy

424
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
424

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A DESCRIPTION OF ADDISON'S DISEASE, AND ITS NEUROPSYCHIATRIC MANIFESTATIONS COMPARING THE DISEASE AS IT IS NOW TO THE DISEASE AS EXPERIENCED BY SAINT ELIZABETH OF THE TRINITY IN 1906.

Psychiatria Danubina·2025
Same author

WHY IS IT IMPORTANT TO STAGE CASES OF SCHIZOPHRENIA?

Psychiatria Danubina·2025
Same author

LESSONS TO BE LEARNT FROM THE UNFORTUNATE CASE OF THE DEATH OF MOLLY RUSSELL.

Psychiatria Danubina·2025
Same author

THE DEATH OF VICTIMS AS A RESULT OF SCHIZOPHRENIA OR OTHER SERIOUS MENTAL ILLNESS; WHAT HAVE WE LEARNT OVER THE YEARS?

Psychiatria Danubina·2025
Same author

HOW SHOULD A DOCTOR REACT WHEN PERSONS EXPRESS A WISH TO SUFFER IN UNION WITH CHRIST? TRUE LOVE AND AN IMPORTANT ISSUE OF NEUROSCIENCE.

Psychiatria Danubina·2025
Same author

SAINT JOHN OF THE CROSS AND THE DEVOTION OF THE NAZZARENO OR REDENTUR; THE STORY OF HOW A SINGLE LOCUTION OR THOUGHT SPREAD ACROSS THE WORLD THROUGH EMBODIED COGNITION AND NEUROSCIENCE.

Psychiatria Danubina·2025
Same journal

Transforming women's mental health with large language models: Opportunities and challenges in digital interventions.

Psychiatria Danubina·2026
Same journal

Impact of cognitive-behavioral therapy for early postpartum depression among primiparous women.

Psychiatria Danubina·2026
Same journal

The impact of housing conditions and nutritional quality on the psycho-emotional state of young internally displaced persons during the Russo-Ukrainian war: The role of secondary stressors.

Psychiatria Danubina·2026
Same journal

Beyond the pandemic: The case for removing obsolete COVID-19 signage in clinical spaces.

Psychiatria Danubina·2026
Same journal

Revamping mariner's mental health using quantum computing techniques.

Psychiatria Danubina·2026
Same journal

Integrating Pilates and myofunctional therapy for better sleep and psychosocial outcomes in obesity-associated obstructive sleep apnea.

Psychiatria Danubina·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.5K

Do atypical antipsychotics improve cognition?

Yasmin Walters1, Mark Agius

  • 1University of Cambridge, School of Clinical Medicine, St. Catharine's College, Cambridge, UK, ylw23@cam.ac.uk.

Psychiatria Danubina
|November 22, 2014
PubMed
Summary
This summary is machine-generated.

Cognitive deficits in schizophrenia remain difficult to treat. Newer antipsychotics and agents targeting the glutamate system show promise, but more research is needed for effective treatments.

More Related Videos

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.4K

Related Experiment Videos

Last Updated: Apr 20, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.5K
Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.4K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Cognitive deficits are a major symptom of schizophrenia.
  • Current treatments for these cognitive impairments are lacking.
  • First-generation antipsychotics and some atypical antipsychotics (e.g., quetiapine, clozapine) have not effectively treated these deficits.

Purpose of the Study:

  • To review the current landscape of treatments for cognitive deficits in schizophrenia.
  • To highlight promising therapeutic avenues beyond traditional antipsychotics.

Main Methods:

  • Review of existing literature on schizophrenia treatment, focusing on cognitive symptoms.
  • Analysis of studies involving newer atypical antipsychotics (asenapine, lurasidone).
  • Examination of research on agents targeting the glutamate system and adjunctive therapies like modafinil.

Main Results:

  • Newer atypical antipsychotics like asenapine and lurasidone show potential for improving cognitive function.
  • Agents modulating the glutamate system are being explored as therapeutic options.
  • Adjunctive treatments, such as modafinil, are under investigation.

Conclusions:

  • Despite some promising agents, effective treatments for schizophrenia-related cognitive deficits are still needed.
  • Further research is required to validate the efficacy of novel antipsychotics, glutamate-targeting agents, and adjunctive therapies.
  • Consolidating findings from ongoing studies is crucial for developing targeted interventions.